Oxytocin
Neurohypophysial Peptide | Social Bonding & Reproductive Hormone
On this page
What is Oxytocin?
Oxytocin is a naturally occurring nine-amino-acid hormone made in the brain, known for its roles in childbirth and lactation. A synthetic version is an FDA-approved medication used in clinical obstetric settings, and researchers separately study it in clinical trials exploring brain and behavioral research questions. Research-grade oxytocin sold here is intended for laboratory study only, not for human use outside licensed clinical settings.
Key terms:
Oxytocin is a synthetic cyclic nonapeptide.
Oxytocin is a peptide hormone of nine amino acids that also acts as a neuropeptide (a nerve-cell signal). The hypothalamus produces it naturally and the posterior pituitary releases it. It is known as the "love hormone" or "bonding hormone." It plays fundamental roles in social bonding, trust, empathy, sexual reproduction, childbirth, and lactation. Synthetic oxytocin (Pitocin/Syntocinon) is FDA-approved for labor induction and postpartum hemorrhage control. Intranasal formulations are being researched for autism spectrum disorders, anxiety, depression, PTSD, chronic pain, and sexual dysfunction.
Key research areas
- FDA-approved for labor induction and postpartum hemorrhage control
- Precise dosing via IV infusion
- Immediate onset
- Well-established safety profile in obstetric settings
Researched dosing
This table reflects the dosing protocols used in FDA-approved obstetric care, established through clinical trials and prescribing information — clinical and research reference, not a self-administration guide.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Labor-induction studies | 0.5-2 mU/min initial, titrate to 1-2 mU/min every 30-60 min | Continuous IV infusion | Intravenous (diluted) |
| Labor-augmentation studies | 0.5-1 mU/min initial, increase gradually | Continuous IV infusion | Intravenous (diluted) |
| Postpartum hemorrhage — prevention | 10 units IM or 10-40 units in IV solution | Single dose after placental delivery | Intramuscular or IV infusion |
| Postpartum hemorrhage — treatment | 10-40 units in 1L IV fluid | Rate adjusted to control bleeding | Intravenous infusion |
How it works
At the cell level, oxytocin research looks at how the hormone binds receptors on uterine muscle cells to trigger contractions — the FDA-approved clinical use — while separate research explores its receptor activity in the brain.
Binds to oxytocin receptors (OXTR) on uterine smooth muscle cells, triggering calcium influx and myometrial contractions. Also stimulates prostaglandin release to enhance uterine sensitivity.
Molecular data
These figures — molecular weight, sequence, chain length — are the chemistry ID researchers use to confirm an oxytocin sample's identity; its ring-shaped (cyclic) structure is a defining feature of this hormone family.
- Weight
- 1007.19 Da
- Length
- 9 amino acids
- Type
- Cyclic nonapeptide
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Pharmacokinetics
This chart shows how quickly oxytocin clears from the body in clinical data — its short half-life is why the FDA-approved medication is given as a continuous IV infusion rather than a single shot.
- Peak
- 0.5 hr
- Half-life
- 0.333 hrs
- Cleared
- ~1.7 hrs
FDA Pitocin Label
Research applications
This section lists the research and clinical areas — FDA-approved obstetric uses alongside separate brain- and behavior-focused clinical trials — that have studied oxytocin; the trial research findings summarized here are not medical claims about what oxytocin will do for any individual.
Obstetric
FDA-approved for initiation or augmentation of uterine contractions when vaginal delivery is medically indicated. FDA-approved for control of postpartum bleeding through uterine contraction stimulation during third stage of labor. Adjunctive therapy for management of incomplete or inevitable abortion in second trimester.
Research
Being researched for autism spectrum disorders, anxiety, depression, PTSD, chronic pain, and sexual dysfunction via intranasal formulations.
Dosage reference
- Doses used in research
- Published protocols used 10–20 units, varying by study setting.
- Frequency in studies
- As clinically indicated under medical supervision
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- IV onset: 1-3 minutes, IM onset: 3-5 minutes, duration 30-60 minutes
- Storage
- Refrigerate 2-8°C, protect from light
- Cycle length
- Single clinical use
- Break between cycles
- As medically indicated
Interactions
This list shows which other hormone- and brain-research peptides scientists study alongside oxytocin, and why.
Reconstitution & storage
Administration and dilution of oxytocin is a hospital procedure performed by healthcare professionals for its FDA-approved use — this section reflects that clinical handling process.
- This is a hospital/clinical procedure performed by healthcare professionals
- Typical dilution: 10 units in 1000mL = 10 mU/mL
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: 2-8°C, use within Per manufacturer expiration date
Reconstituted: 2-6°C, use within 48-72 hours multi-dose; single-dose aliquots may be frozen
Open the Oxytocin reconstitution calculatorQuality indicators
These are the pharmaceutical-labeling and solution-clarity checks used to confirm an FDA-approved oxytocin product is genuine and hasn't degraded.
FDA-approved pharmaceutical product - Use only FDA-approved oxytocin injection (Pitocin) from licensed pharmacies
Clear, colorless solution - Oxytocin injection should be clear without particles or discoloration
Proper packaging and labeling - Verify lot number, expiration date, and concentration (10 units/mL typical)
Cloudy or discolored solution - Do not use if solution appears cloudy, contains particles, or is discolored
Requires clinical setting - Injectable oxytocin should only be administered in clinical settings with proper monitoring
Safety notes
This section covers oxytocin's FDA-approved regulatory status and clinical safety monitoring requirements — reference context from its approved medical use, not guidance for self-administration.
- Must be administered only by qualified healthcare professionals
- Requires continuous electronic fetal monitoring during labor
- Uterine hyperstimulation is the primary concern - can cause fetal distress
- Contraindicated in certain obstetric conditions (see prescribing information)
- Water intoxication risk with high doses or prolonged infusion
- Have tocolytic agents available for uterine hyperstimulation
- FDA-approved for labor induction (Pitocin/Syntocinon)
- FDA-approved for postpartum hemorrhage control
Regulatory status
- Approved by the FDA for at least one indication. That approval applies to regulated pharmaceutical products, not to research-grade material.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Treatment did not result in weight reduction but showed significant reduction in caloric intake at test meals and improvement in mental health-related quality of life. No serious adverse events.
While no significant advantage over placebo on primary social cognition outcomes, oxytocin showed modest improvement in social functioning and within-group reduction in negative symptoms.
Large randomized controlled trial found intranasal oxytocin did not significantly improve social functioning in children and adolescents with ASD compared to placebo, highlighting need for better patient selection and dosing strategies.